Skip to main content
. 2021 Apr 14;16(4):e0243333. doi: 10.1371/journal.pone.0243333

Fig 1. Performance and validation of the Biomark-HD SARS-CoV-2 qPCR assay.

Fig 1

(A) Titration of the diluted (N) nucleocapside spike-in transcript. A serial dilution of the synthetic N transcript from 2.104 to 2 copies was performed and processed through the Biomark-HD protocol. Correlation and amplification curves of detected Cq values according to synthetic N transcript copy number obtained with N1 primers/probe are shown. (B) Amplification curves showing the range of detection of a SARS-CoV-2 positive clinical sample serial dilution with N1 and E primers/probe. (C) Typical amplification curves showing the combination of two primers/probe sets on 3 SARS-CoV-2 positive clinical samples. Mix #1: E, N1, human RNP. Mix #2: E, N, ORF1ab and human RNP. (D) Validation of the Biomark-HD protocol on a cohort of 18 biopsies from positive patients. The correlation of the Cq values obtained for the N, E and the ORF1ab genes are presented. The data presented are representative of at least two independent experiments performed in quadruplicate.